Vor Biopharma (NASDAQ:VOR) 株価情報

VOR BIOPHARMA INC

Vor Biopharma

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Vor Biopharma Inc

Virgin Orbit Holdings Inc

Virgin Orbit Holdings Inc Warrants (29/12/2026)

Vornado Realty Trust

VORNADO RLTY TR 6.50 A PR by Vornado Realty Trust

Vornado Realty Trust 5.25% Series M Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share, no par value per share

Vornado Realty Trust 5.25% Series N Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share

Vornado Realty Trust 4.45% Series O Cumulative Redeemable Preferred Shares, Liquidation Preference $25.00 Per Share

Vortex Brands Co

VORTEX ENERGY CORP by Vortex Energy Corp.

Vortex Energy Corp

Vortex Energy Corp Ordinary Shares

Vortex Metals Inc

Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

Needham Reiterates Hold on AppLovinto Hold

Rosenblatt analyst Kevin Cassidy maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $172 to $200.

Price Target

Rosenblatt Maintains Buy on Micron Technology, Raises Price Target to $200

CRISPR Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310&#x2122;, targeting ANGPTL3, as well as continued progress on CTX320&#x2122;, targeting the LPA gene, and CTX340&#x2122;, targeting the AGT gene.
"CRISPR Therapeutics remains focused on executing against our strategic priorities and advancing our portfolio of innovative therapies," said&nbsp;Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of&nbsp;CRISPR Therapeutics. "The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. We are progressing with our dose-finding study and expect to share complete data at a medical meeting in the second half of this year. For CTX320, we are continuing our dose-finding study and anticipate sharing data in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape."
CTX310, targeting ANGPTL3
<ul>
<li>CTX310 targets&nbsp;ANGPTL3, a gene that encodes for key protein involved in the regulation of low-density lipoprotein (LDL) and triglyceride (TG) levels – both of which are recognized risk factors for atherosclerotic heart disease (ASCVD). Loss-of-function mutations in ANGPTL3 are associated with significantly reduced levels of LDL and TGs, as well as reduced risk of ASCVD, without known adverse health effects. More than 40 million patients in the U.S. alone are affected by elevated LDL, severely elevated TG or both – representing a significant unmet need and a large addressable population. CTX310 is initially focused on high-risk patients with the greatest unmet medical need and limited effective treatment options.&nbsp;</li>
<li>CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (MDL). Eligible participants have levels of TG &gt;300 mg/dL and/or LDL-C &gt;100 mg/dL (or &gt;70 mg/dL for subjects with ASCVD). Both LDL and TG are validated surrogate endpoints accepted by regulatory agencies.</li>
<li>These new results build upon previously disclosed results from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant. As dose-range finding continues, data to date demonstrate peak reductions of up to 82% in TG and LDL reductions of up to 86% at DL4 without any clinically significant changes in liver enzymes and a safety and tolerability profile consistent with previous findings.</li>
<li>The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.</li>
</ul>
CTX320&#x2122;, targeting LPA
<ul>
<li>CTX320 is in an ongoing Phase 1 clinical trial targeting the&nbsp;LPA&nbsp;gene in patients with elevated lipoprotein(a) [Lp(a)], a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events (MACE). Elevated Lp(a) levels affect up to 20% of the global population and remains unaddressed by current therapies.</li>
<li>The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape.</li>
</ul>
CTX340, targeting angiotensinogen (AGT)
<ul>
<li>CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen (AGT) for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies.</li>
</ul>

CRSP

CRISPR Therapeutics Reports Progress on Gene-Based Treatments for Cardiovascular Diseases with New Data on CTX310 and CTX320

SERV

Serve Robotics Expands Autonomous Delivery Service To Atlanta With Uber Eats, Shake Shack, And Local Favorites

Organizations require proactive PQC readiness strategies to safeguard assets, preserve customer trust, and uphold compliance mandates
F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), the global leader in delivering and securing every app and API, is helping customers prepare for the foundational cybersecurity shift presented by quantum computing. New comprehensive post-quantum cryptography (PQC) readiness solutions are seamlessly integrated into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.f5.com%2Fproducts%2Ff5-application-delivery-and-security-platform&amp;esheet=54282466&amp;newsitemid=20250626252498&amp;lan=en-US&amp;anchor=F5+Application+Delivery+and+Security+Platform&amp;index=1&amp;md5=067e6dbe9e6be9fe40df666102affb22">F5 Application Delivery and Security Platform</a>, equipping organizations with the tools they need to secure applications and APIs while maintaining high performance and scalability.

FFIV

F5 Launches PQC Readiness Solutions To Secure Apps And APIs

LTRX

Lantronix Secures Multi-Year Deal With Tier-1 US Wireless Operator To Digitally Monitor 50,000+ Backup Generators For Enhanced Network Reliability

<a href="https://www.globenewswire.com/Tracker?data=iu-BaN1J6h2DCCdb4JH88Dcdb-bOBYnLmQi2cHJDIttnRAghQgbfFgLzbR2I5gOSCyd1TrijwPxcuGY1SvZhNQ==">GXO Logistics, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), the world's largest pure-play contract logistics provider, today announced the launch of <a href="https://www.globenewswire.com/Tracker?data=IOMI2bqN1zRScaDUVLy768OpQwv18SMwQgmxVD8G9xtNI4GcR57K8tdgQ-hxjuzeX911XoXdGzzpYiIinQkBcdDMt9XvihPOIWrnJd8-J50=">GXO IQ</a>, the first AI-powered intelligent platform built for the logistics industry by logistics experts. GXO IQ will help businesses navigate the complexity of today's global supply chains by deploying industry-leading AI capabilities that orchestrate more productive, more dynamic logistics operations.
"Today marks a milestone for GXO and a pivotal moment for the industry as we launch GXO IQ, the first-ever AI-powered, cloud native operating system developed specifically for logistics," said Nizar Trigui, Chief Technology Officer of GXO. "There are few environments more dynamic or complex than a modern warehouse. Thousands of micro decisions are made every day in every site. As throughput increases, experts need a system that thinks with them to effectively anticipate, manage and orchestrate operations intelligently. That's exactly why GXO IQ was built - to be the logistics operating system of the future."
Informed by over 20 years of operational data, GXO IQ leverages a suite of proprietary AI algorithms that intelligently orchestrate millions of complex, multi-step actions across inventory distribution and movement, order picking and packing, shipping, and staffing. GXO IQ was designed by logistics experts and leverages a best-in-class technology stack including Google Cloud's Vertex AI and Snowflake Cortex AI. The tool also leverages Google Cloud's API management product Apigee to give customers secure and seamless access to critical warehouse data.&nbsp;&nbsp;
GXO IQ is comprised of four layers that create a seamless, intelligent operating platform:
<ul>
<li>Data Fabric Layer: GXO IQ utilizes GXO's operational expertise from 20 years of deploying supply chain solutions for customers, along with inputs from thousands of frontline operators, and a data lake that utilizes billions of transactions from GXO operations. Every day, over 200 million signals are streamed and organized to form the data fabric of the platform that trains powerful AI algorithms on every aspect of logistics operations.</li>
<li>AI Orchestration Layer: The AI algorithms are continuously running in the background, predicting demand shifts, anticipating inventory risks, proactively initiating inventory movement, and identifying the ideal pick, pack, and ship process of each order - all in real-time.</li>
<li>End-to-End Execution Layer: The execution layer is comprised of a full suite of logistics management capabilities with marketplace integration and value-added micro-services, including order management, warehousing, returns, and transportation. Services are fully integrated into a cohesive end-to-end solution that can be customized to meet the evolving needs of each individual customer using the platform.</li>
<li>Experience Layer: A unique, persona-based interface with a native, interactive AI agent called ‘GIL' provides a single view to see what's important and help manage the entire process, from real-time order fulfilment status to exceptions management to inventory risk alerts. GIL offers interactive insights that identify opportunities, answers questions and translates complexities into executable recommendations.</li>
</ul>

GXO Logistics Launches GXO IQ, an AI-Powered Platform to Transform Global Supply Chains

Keybanc analyst Jeffrey Hammond upgrades Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) from Sector Weight to Overweight and maintains the price target from $40 to $40.

Upgrades

HLIO

Keybanc Upgrades Helios Technologies to Overweight, Maintains Price Target to $40

KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE).
"We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE," said Ben Palleiko, CEO of KalVista. "This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care."
Financial terms of the agreement are not being disclosed.

KALV

KalVista Partners with Pendopharm to Bring Sebetralstat to Canada for Hereditary Angioedema Treatment

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks
Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis
Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis
Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks
Weight loss of up to 6.2% at 24 weeks with no plateauing
Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants
Conference call to be held on June 26, 2025 at 8:30 am ET
GAITHERSBURG, Md., June 26, 2025 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=YOr6zKCgGqQv3F1roOZpxCdTUklm3pOuPVaxhGdxtVG3jSUzpwhMZKmQoXcfK34GebAUEtaHt8auaaRaQOTAqw==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced positive topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks. Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment. In an intent-to-treat (ITT) analysis, in which participants with missing biopsies were considered non-responders, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% and 52.1% for pemvidutide 1.2 mg and 1.8 mg, respectively versus 19.1% for placebo (p&lt; 0.0001 both doses). The effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant). A supplemental AI-based analysis demonstrated statistically significant reductions in fibrosis, including 30.6% of participants receiving pemvidutide 1.8 mg achieving a 60% or more reduction in fibrosis compared to 8.2% receiving placebo (p&lt; 0.001). Statistically significant changes in well-established non-invasive tests (NITs) of fibrosis, including Enhanced Liver Fibrosis score (ELF) and Vibration-Controlled Transient Elastography (VCTE) were also observed compared with placebo at both doses. Together, these data suggest strong evidence of anti-fibrotic activity of pemvidutide in the MASH population. At 24 weeks, mean weight loss in pemvidutide-treated participants was 5.0% and 6.2% at the 1.2 mg and 1.8 mg doses, respectively, versus 1.0% in the placebo arm (p&lt; 0.001, both doses). Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication.

Altimmune Announces Topline Results From IMPACT Phase 2b Trial Of Pemvidutide In MASH; Trial Meets "Primary Endpoint With Statistically Significant MASH Resolution Without Worsening Of Fibrosis In Up To 59.1% Of Participants In ITT Analysis"

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.

PTGX

Protagonist Therapeutics to Reveal Oral Obesity Drug Development Candidate and Study Results in Upcoming Call

Earnings

Walgreens Boots Alliance Q3 2025 Adj. EPS $0.38 Beats $0.34 Estimate, Sales $38.99B Beat $36.84B Estimate

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced its collaboration with NVIDIA as part of the Automatica 2025 robotics and automation showcase. The collaboration highlights how Cyngn is leveraging the NVIDIA Isaac robotics platform to power next-generation autonomous vehicle solutions for industrial applications.
&nbsp;
As featured in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457472-1&amp;h=3858890335&amp;u=https%3A%2F%2Fblogs.nvidia.com%2Fblog%2Fautomatica-robotics-2025%2F&amp;a=NVIDIA%27s+recent+blog+post">NVIDIA's recent blog post</a>, Cyngn was selected among a handful of robotics innovators using NVIDIA Isaac technologies to accelerate safe, scalable autonomy across dynamic, real-world environments. Automatica 2025, the world's leading trade fair for smart automation and robotics, provides a global stage for demonstrating how AI-powered solutions are transforming manufacturing and logistics.
Cyngn's autonomous industrial vehicles, built on NVIDIA Isaac and powered by Cyngn's proprietary DriveMod software, are currently operating in commercial environments to reduce labor costs, increase throughput, and improve safety.

NVDA

Cyngn Partners with NVIDIA to Showcase Autonomous Industrial Vehicles at Automatica 2025

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) with a Buy and maintains $7 price target.

BTBT

HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target

PolicyNote's Ease of Use and Quick Time-to-Value Enable Worldwide Scale
Potential Stablecoin Integration Could Further Facilitate International Expansion
FiscalNote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>), a leading AI-driven policy and regulatory intelligence company, today announced that PolicyNote, its next-generation flagship platform, now surpasses the legacy FiscalNote platform in daily active users, a key milestone in customer engagement and product adoption. The rapid growth is fueled by PolicyNote's intuitive design and quick time-to-value, enabling customers to achieve results with minimal friction. As FiscalNote continues to enhance PolicyNote, it expects to unlock incremental long-term international growth by enabling global organizations to discover, provision, and realize value from the platform without the need for significant support. To facilitate this expansion and streamline cross-border transactions, the Company is evaluating the use of stablecoins as a payment option for international customers.

NOTE

FiscalNote Announces PolicyNote Now Surpasses FiscalNote Platform In Daily Active Users

Aurora Cannabis Expands Compassionate Pricing Program In Canada, Raises Income Eligibility To $60K To Boost Medical Access

LASE

Laser Photonics To Acquire Beamer Laser Marking Systems Assets, Expanding U.S.-Made Offerings And Boosting Industrial Laser Market Reach

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $30 price target.

ACAD

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $30 Price Target

enCore Energy Hits Record Uranium Extraction At Alta Mesa, Averaging Over 3,000 Lbs/Day; Texas Law Boosts Nuclear Permitting Efficiency

<ul>
<li>Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to injection site and infusion reactions with no serious or severe adverse events observed</li>
<li>Following a single dose, serum concentrations of VYD2311 remained high at six months with an observed half-life of the IM dose route having the longest duration at 76.0 (CI: 68.5 – 90.7) days</li>
<li>Comprehensive dose modeling of VYD2311 sVNA titers (submitted to FDA and under preparation for publication) indicates possible strong protection from symptomatic COVID-19 achievable via IM dosing on a long interval (months to quarters and beyond)</li>
<li>Type C meeting scheduled with FDA for early Q3 to discuss registration-directed next steps for the VYD2311 program and overall approval pathway for Invivyd COVID-19 monoclonal antibodies</li>
</ul>
WALTHAM, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced full Phase 1/2 clinical data for VYD2311, a next-generation monoclonal antibody (mAb) candidate designed to prevent and treat COVID-19.
VYD2311 builds on the success of Invivyd's first-generation mAb, pemivibart, which received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12&nbsp;years of age and older weighing at least 40&nbsp;kg) who have moderate to-severe immune compromise. VYD2311 is 99%+ structurally identical to predicate antibodies adintrevimab and pemivibart, and represents the result of a technologically enabled, directed change in antibody sequence and spike protein target engagement uniquely accessible via Invivyd's technology platform. These subtle but critical molecular changes for VYD2311 confer an increase in in vitro potency and a differentiated resistance profile compared to pemivibart, with corresponding potential improvements in clinical profile and accessibility, if approved. VYD2311 is now the third mAb from Invivyd to undergo randomized clinical trial evaluation while retaining a near-identical molecular structure and target binding site on the SARS-CoV-2 spike protein, a feature of Invivyd's platform designed to provide vulnerable populations, healthcare professionals (HCPs), and regulatory authorities with a steady stream of high-assurance, minimally altered mAbs sufficient to navigate natural SARS-CoV-2 evolution rapidly with a non-vaccine approach.
The Phase 1/2 study of VYD2311 was a randomized, double-blind, first-in-human clinical trial evaluating the safety and clinical pharmacokinetic (PK) profile of VYD2311 in 40 subjects across multiple routes of administration (ROAs) and dose levels for a single dose, and includes VYD2311 dosed intravenously (IV), intramuscularly (IM), and subcutaneously (SC) in four cohorts of 10 participants each, randomized 8:2 to receive drug or placebo. This range of ROAs and doses was tested to provide maximum flexibility in designing registrational pathways for both COVID-19 prophylaxis and treatment, while retaining a high barrier to resistance in the form of doses expected to accommodate significant evolutionary changes in SARS-CoV-2 viruses.
VYD2311 was well tolerated with all adverse events (AEs) considered mild to moderate in severity with no serious or severe AEs reported. All AEs were deemed unrelated to study drug, or as expected and largely related to injection site erythema, injection site pain, injection site swelling, headache, dizziness, and infusion-related reactions, one of which (Grade 2) required an infusion interruption and was later restarted without any further reaction.
A formal estimate of in vivo half-life based on full Phase 1/2 clinical trial data confirmed the long half-life of VYD2311. At six months (end of study follow-up), serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of pemivibart. Specifically, half-life estimates by cohort ranged from 61 days (high dose IV) to 76 days (IM) as compared to pemivibart estimated half-life of 49 days. VYD2311's long half-life could allow meaningful, long-term protection from symptomatic disease, potentially over multiple quarters, which is expected to be more durable than a COVID-19 vaccine, given rapid waning of protective benefit. High dose IV administration could similarly provide very long-term follow-up viral suppression in a COVID-19 treatment use case.
In addition to assessing safety and tolerability of VYD2311 across the various ROAs, a comprehensive dose modeling analysis was conducted to support development discussions with FDA and other global regulators about a rational dosing paradigm for VYD2311 and follow-on COVID-19 mAbs. A Cox model analysis was employed using data from Invivyd's recent CANOPY Phase 3 clinical trial for pemivibart, incorporating both serum virus neutralizing antibody (sVNA) titers and long-term clinical efficacy data to provide a robust foundation on which to reevaluate titer thresholds used to define efficacy for immunobridging purposes for both immunocompetent and immunocompromised (IC) individuals.
The VYD2311 dose modeling strategy contemplated a range of doses for IV up to 4500 mg, doses for IM up to 1000 mg, and doses for SC up to 750 mg. The results of this most recent analysis align well with prior published estimates of relationships between sVNA titers and observed clinical efficacy across multiple COVID-19 mAbs. Key findings of Invivyd's updated dose modeling analysis include:
<ul>
<li>Robust Modeled Protective Efficacy: All dosing routes and doses assessed yielded modeled efficacy rates that appear to eclipse estimated contemporary rates of COVID-19 vaccine protection for both IC and non-IC individuals. Notably, IM and SC dosing every three months reflected robust efficacy for both IC and non-IC individuals and such routes could simplify and scale administration, improving convenience.</li>
<li>IM Dosing Comparable Performance to IV for Prevention: Modeling data indicate that IM administration can offer efficacy comparable to high dose IV dosing. Critically, the IM route could eliminate the need for IV infrastructure - enhancing tolerability, accessibility, and convenience.</li>
<li>Very High Antiviral Titers Available via IV for Treatment of Active Infection: Antiviral titers conferred by VYD2311 via IV to treat active infection are expected to substantially exceed the titers conferred by pemivibart and provide longer suppression of virus compared to pemivibart, and would seem to meet the criteria previously suggested by the FDA as persuasive of expected treatment effect in prior correspondence to Invivyd.</li>
</ul>
Invivyd plans to discuss approval pathways for VYD2311 and follow-on COVID-19 mAbs with the FDA early in the third quarter of 2025, and expects to announce additional information about the VYD2311 program throughout 2025. Invivyd expects those discussions will include approval pathways for treatment of active COVID-19 and prophylaxis for vulnerable populations including the elderly, the immunocompromised, and pediatric populations including neonates and infants.

IVVD

Invivyd Announces Full Phase 1/2 Clinical Data For VYD2311, Next-Gen Monoclonal Antibody Candidate Designed To Prevent And Treat COVID-19

Financing

Press Releases

Vor Bio Announces $55.6 Million Private Placement

Management

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Health Care

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

PureTech Announces Annual Results for Year Ended December 31, 2024

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces $175 Million Private Placement

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

Comments

Vor Biopharma

ニュース

パートナーシップ

ベンジンガ・グローバル